Cargando…
First-line immune-chemotherapy combination for squamous NSCLC is already a reality
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354107/ https://www.ncbi.nlm.nih.gov/pubmed/32676345 http://dx.doi.org/10.21037/tlcr.2020.03.36 |
| _version_ | 1783558015098552320 |
|---|---|
| author | Hendriks, Lizza E. L. Menis, Jessica Remon, Jordi |
| author_facet | Hendriks, Lizza E. L. Menis, Jessica Remon, Jordi |
| author_sort | Hendriks, Lizza E. L. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7354107 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-73541072020-07-15 First-line immune-chemotherapy combination for squamous NSCLC is already a reality Hendriks, Lizza E. L. Menis, Jessica Remon, Jordi Transl Lung Cancer Res Editorial Commentary AME Publishing Company 2020-06 /pmc/articles/PMC7354107/ /pubmed/32676345 http://dx.doi.org/10.21037/tlcr.2020.03.36 Text en 2020 Translational Lung Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Commentary Hendriks, Lizza E. L. Menis, Jessica Remon, Jordi First-line immune-chemotherapy combination for squamous NSCLC is already a reality |
| title | First-line immune-chemotherapy combination for squamous NSCLC is already a reality |
| title_full | First-line immune-chemotherapy combination for squamous NSCLC is already a reality |
| title_fullStr | First-line immune-chemotherapy combination for squamous NSCLC is already a reality |
| title_full_unstemmed | First-line immune-chemotherapy combination for squamous NSCLC is already a reality |
| title_short | First-line immune-chemotherapy combination for squamous NSCLC is already a reality |
| title_sort | first-line immune-chemotherapy combination for squamous nsclc is already a reality |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354107/ https://www.ncbi.nlm.nih.gov/pubmed/32676345 http://dx.doi.org/10.21037/tlcr.2020.03.36 |
| work_keys_str_mv | AT hendrikslizzael firstlineimmunechemotherapycombinationforsquamousnsclcisalreadyareality AT menisjessica firstlineimmunechemotherapycombinationforsquamousnsclcisalreadyareality AT remonjordi firstlineimmunechemotherapycombinationforsquamousnsclcisalreadyareality |